Amyloidosis News and Research

RSS
Amyloidosis is the term applied to a group of conditions caused by deposits of an abnormal protein called amyloid. This rare but serious condition affects between 1 and 5 people in every 100,000 each year in the UK. The condition is mainly seen among the elderly.
Researchers find molecular mechanism that may be responsible for development of amyloidoses

Researchers find molecular mechanism that may be responsible for development of amyloidoses

Approval to start trial of Videregen's replacement trachea technology

Approval to start trial of Videregen's replacement trachea technology

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Isis Pharmaceuticals begins ISIS-FXI Rx Phase 2 study in patients with ESRD on hemodialysis

Isis Pharmaceuticals begins ISIS-FXI Rx Phase 2 study in patients with ESRD on hemodialysis

Discovery may lead to development of cell-based regenerative therapy to restore thyroid function

Discovery may lead to development of cell-based regenerative therapy to restore thyroid function

OSU discovery sheds new light on how proteins fold

OSU discovery sheds new light on how proteins fold

FDA awards research grants to boost product development for patients with rare diseases

FDA awards research grants to boost product development for patients with rare diseases

Light-chain amyloidosis patients treated with high-dose chemo and stem cell transplantation have long-term survival

Light-chain amyloidosis patients treated with high-dose chemo and stem cell transplantation have long-term survival

Amyloid-beta kinetics reveal link between aging and AD risk

Amyloid-beta kinetics reveal link between aging and AD risk

Isis Pharmaceuticals, AstraZeneca to develop antisense therapies for cardiovascular, metabolic, renal diseases

Isis Pharmaceuticals, AstraZeneca to develop antisense therapies for cardiovascular, metabolic, renal diseases

NEJM publishes positive clinical results from Phase 2 clinical study of volanesorsen

NEJM publishes positive clinical results from Phase 2 clinical study of volanesorsen

Isis Pharmaceuticals receives $2.15 million milestone payment to advance ISIS-SMN Rx study in children with SMA

Isis Pharmaceuticals receives $2.15 million milestone payment to advance ISIS-SMN Rx study in children with SMA

Akcea Therapeutics obtains FDA Orphan Drug Designation for volanesorsen

Akcea Therapeutics obtains FDA Orphan Drug Designation for volanesorsen

More support for amyloidosis as earliest AD biomarker

More support for amyloidosis as earliest AD biomarker

Isis Pharmaceuticals provides update on ISIS-SMN Rx Phase 2 study in children with SMA

Isis Pharmaceuticals provides update on ISIS-SMN Rx Phase 2 study in children with SMA

Isis Pharmaceuticals provides update on ISIS-SMN Rx Phase 2 clinical study in infants with Type I SMA

Isis Pharmaceuticals provides update on ISIS-SMN Rx Phase 2 clinical study in infants with Type I SMA

Stemedica receives FDA's IND approval for itMSC Phase IIa clinical trial to treat Alzheimer's disease

Stemedica receives FDA's IND approval for itMSC Phase IIa clinical trial to treat Alzheimer's disease

Alnylam announces clinical data from patisiran Phase 2 OLE study for treatment of patients with FAP

Alnylam announces clinical data from patisiran Phase 2 OLE study for treatment of patients with FAP

Isis Pharmaceuticals announces positive results from ISIS-ANGPTL3Rx Phase 1 study

Isis Pharmaceuticals announces positive results from ISIS-ANGPTL3Rx Phase 1 study

Royal Free London NHS Foundation Trust deploys OpenText to manage patient medical care records

Royal Free London NHS Foundation Trust deploys OpenText to manage patient medical care records